A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.
A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.
PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been submitted in Spain. The full title of the application is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.” Based on a strategic company decision, PharmNovo has submitted the CTA, in the first instance, to the Spanish Health Authorities only. Submission to the Czech Republic and Poland, the two other countries in which the trial will be conducted, is planned to take place following approval in Spain, which is expected by October 2025. Subject to additional investment, patient enrolment is expected to start by Quarter 1 2026.
Read moreTake the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Congress in April 2025 in London. PharmNovo is redefining pain management with PN6047, a first-in-class Delta Opioid Receptor Agonist (DORA), safer, non-addictive solution for neuropathic pain. Unlike traditional opioids, PN6047 eliminates concerns of side effects, abuse potential, and tolerance. With a proven safety profile from Phase I trials and a market projected to exceed EUR 13 billion by 2033, PN6047 is set to be a game-changer.
Read morePharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.
Read morePharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.
Read more